CDKN1A is altered in 0.96% of malignant solid tumor patients with CDKN1A Mutation present in 0.48% of all malignant solid tumor patients [4].

CDKN1A Mutation is an inclusion criterion in 5 clinical trials for malignant solid tumor, of which 3 are open and 2 are closed. Of the trials that contain CDKN1A Mutation and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [5].

CDKN1A is altered in 0.54% of colorectal carcinoma patients with CDKN1A Mutation present in 0.39% of all colorectal carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDKN1A Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

CDKN1A is altered in 0.49% of non-hodgkin lymphoma patients with CDKN1A Mutation present in 0.32% of all non-hodgkin lymphoma patients [4].

CDKN1A Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN1A Mutation and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDKN1A is altered in 0.41% of breast carcinoma patients with CDKN1A Mutation present in 0.27% of all breast carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDKN1A Mutation and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [5].

CDKN1A is altered in 11.99% of bladder carcinoma patients with CDKN1A Mutation present in 3.89% of all bladder carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A is altered in 1.54% of melanoma patients with CDKN1A Mutation present in 0.83% of all melanoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A is altered in 0.61% of esophageal carcinoma patients with CDKN1A Mutation present in 0.49% of all esophageal carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDKN1A is altered in 1.0% of ovarian carcinoma patients with CDKN1A Mutation present in 0.4% of all ovarian carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A is altered in 0.39% of gastric carcinoma patients with CDKN1A Mutation present in 0.39% of all gastric carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDKN1A is altered in 0.64% of lymphoma patients with CDKN1A Mutation present in 0.38% of all lymphoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A is altered in 0.35% of glioblastoma patients with CDKN1A Mutation present in 0.31% of all glioblastoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A is altered in 0.67% of head and neck carcinoma patients with CDKN1A Mutation present in 0.31% of all head and neck carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A is altered in 0.44% of non-small cell lung carcinoma patients with CDKN1A Mutation present in 0.3% of all non-small cell lung carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A is altered in 0.28% of germ cell tumor patients with CDKN1A Mutation present in 0.28% of all germ cell tumor patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

CDKN1A is altered in 0.27% of pancreatic carcinoma patients with CDKN1A Mutation present in 0.19% of all pancreatic carcinoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A is altered in 0.6% of sarcoma patients with CDKN1A Mutation present in 0.08% of all sarcoma patients [4].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

CDKN1A Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDKN1A Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].